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ABSTRACT 
Recent era has witnessed an inordinate rise in the demand for radiopharmaceuticals due to their multifarious biomedical and clinical 
application. Scientific fraternity worldwide is continuously working in developing different innovative radiopharmaceuticals of immense clinical 
importance both from specialized theranostics and personalized medicine point of view. However, this increased production and use of 
radiopharmaceuticals in various nuclear medicine procedures have been accompanied by an inevitable problem concerning their storage after 
use and final disposal. Keeping in view the inherently hazardous nature of radiopharmaceuticals due to the presence of radionuclide in them, it is 
imperative to have an adequate regulatory backup which if followed meticulously can assure their safe storage and disposal so that threat to 
men and environment is prevented. The present work has been aimed to draft comprehensive regulatory guidelines for the storage and disposal 
of radiopharmaceuticals which is in resonance with the global standards. For this, the methodology consisting of a thorough research of existing 
guidelines from Atomic Energy Regulatory Board (AERB) exclusively on storage and disposal of radiopharmaceuticals in India has been done 
with the objective to identify and select various parameters not yet explicitly covered as is their scope. The guideline has been made to suitably 
address all sorts of necessary documentation, allocation of responsibility, ways of waste prevention, various mechanisms to deal with 
radiopharmaceuticals waste in all forms of matter and suggestive recommendations.  
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INTRODUCTION 
Storage and disposal of radiopharmaceuticals constitute an 
important step in the lifecycle management of 
radiopharmaceuticals. Technically, storage and disposal are 
two different terms. The term ‘storage’ relates to placement 
of radiopharmaceutical waste in an appropriate facility with 
the intention of retrieving it at some point of time in the 
future. The term ‘disposal’, on the other hand, refers to 
emplacement of radiopharmaceutical waste into a suitable 
waste management facility or location with no intention of 
retrieving in the future. The production of most of the 
radiopharmaceuticals and their application on patients is 
accompanied by radiopharmaceutical waste chiefly 
consisting of beta and gamma emitting radionuclides that 
lose half of their radioactivity in periods ranging from a few 
hours to some days 1,2. Alpha emitting radionuclides are 
limited to only trace quantities. The production of 
radiopharmaceuticals consists of irradiating the parent 
nuclide to produce daughter radionuclide in which other 
unwanted radionuclides may also creep in and constitute the 
radiopharmaceutical wastes3. It is estimated that as much as 
95% of the original radioactive material during 
manufacturing of radiopharmaceuticals may be rejected as 
waste. Moreover, many radiopharmaceuticals consisting of 
radionuclides chiefly carbon-14, phosphorus-32, 
phosphorus-33, sulfur-35 and iodine-125 finds their 
applications in various theranostic procedures in nuclear 
medicine centres, leading to the production of wastes in 
various forms of matter4,5.   
Keeping in view the hazardous nature of 
radiopharmaceuticals and the varied form in which the 
radiopharmaceutical waste can be obtained, including 
discrete sealed or unsealed radiation sources, it is 
indispensable to design relevant methods and regulatory 
actions for their organized and effective storage and disposal 
at institutional as well as national level that meets the 
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demand of safety both for men and environment 6. The first 
and leading most way for effectively dealing with 
radiopharmaceutical waste is following the ‘Waste 
Hierarchy’ concept which aims at minimizing the waste 
generation at each and every step. Figure 1 presents an 
overview of ‘Waste Hierarchy’.  
Most Preferred 
 
Least Preferred  
Figure 1: Waste hierarchy concept for management of 
radiopharmaceutical waste. 
Also important is to implement these regulations effectively 
by following a monitoring mechanism that ensures that the 
rules laid down are properly adhered7. The focus should be 
made to meticulously design a regulatory infrastructure that 
allows for protection of occupational workers and 
community as whole dealing with these hazardous agents 
and a way to take legal recourse for loss incurred while 
dealing with them. An effective radiopharmaceutical waste 
management regulation should also consist of a well-defined 
radiation protection program. Therefore, the management of 
such a waste of varied half-life needs an effective 
management at the outset which should be inherent in the 
regulatory setup before the commencement of any nuclear 
medicine facility.  
OBJECTIVES 
Guidelines for disposal of radiopharmaceuticals, particularly 
in India, were systematically reviewed for their content and 
completeness so that disposal of radiopharmaceuticals does 
not pose any significant hazard both to the society as well as 
to the environment. The focus was to identify and select 
various parameters not yet included in the guidelines 
exclusively meant for the storage and disposal of 
radiopharmaceuticals in India. On the basis of careful 
scrutiny of various parameters, a draft has been made which, 
if followed meticulously, can bring about adequate 
monitoring, management and disposal of 
radiopharmaceuticals in India so that threat to men and 
environment from the radiopharmaceuticals is prevented.  
METHODOLOGY 
A comprehensive and relevant research on the existing 
guidelines by Atomic Energy Regulatory Board (AERB) on 
disposal of radiopharmaceuticals in Indian scenario has been 
done. Atomic Energy Regulatory Board (AERB) is the 
premier most agency for radiopharmaceuticals and their 
regulations in India and is under the overarching 
surveillance of Department of Atomic Energy (DAE), 
Government of India. AERB has framed many mandatory 
requirements in form of various codes, rules and guides for 
exercising its regulatory effect on radiopharmaceuticals in 
India. Concerning disposal, it has issued Atomic Energy (Safe 
Disposal of Radioactive Waste) Rules, G.S.R. 125, 19878 and 
other code named Management of Radioactive Waste, 20079. 
Apart from it, it has also issued another safety code named 
Nuclear Medicine Facilities, 2010 which covers the whole 
spectrum of operations commencing from the approval of 
the site, it's setting up and design to the ultimate 
decommissioning10. Some specifications concerning disposal 
have also been mentioned in it along with other relevant 
guidelines by AERB. However, none of these guidelines and 
codes explicitly details the requirement for disposal of 
radiopharmaceuticals exclusively in a detailed manner which 
is in line with the global standards. The work has been aimed 
to fill this regulatory void in the present regulatory 
landscape concerning radiopharmaceuticals in India and 
drafting of comprehensive regulatory guidelines of global 
standard. Radiopharmaceuticals waste are available in all 
form of matter and therefore regulatory guidelines should 
address each of them adequately11.  
Solid radiopharmaceuticals wastes 
Solid radiopharmaceutical waste consists of used 
radionuclide generator, waste obtained during production of 
radionuclides from particle accelerator and nuclear reactors, 
radiopharmaceutical kit after use at the end of their expiry 
date/time, contaminated drinking straws used by the 
patients, contaminated swabs, vessels, needles, gloves and 
syringes used in production of radiopharmaceuticals, 
contaminated hospital gowning, towels, bed covers, 
absorbent papers, laboratory bench top coverings and 
removable tiles, contaminated glass wares consisting of 
pipettes, scalpels, measuring cylinders, syringes, needles, 
glass slides, plastic containers, blood lancets, conical flasks 
used for performing various in vitro tests, contaminated 
media and disposable plastic tips of radioimmunoassay test, 
animal carcasses, lead pots used for decay in storage 
contaminated with radioactive material, and spent and 
disused sealed sources at the end of their useful life. 
Liquid radiopharmaceutical waste 
This type of waste chiefly consists of wastewater from 
decontamination of contaminated radiation patients/victims, 
equipment and glass wares, radioactive stock and standard 
solution remaining unused at the end, unused and opened 
radiopharmaceuticals and labelled compounds, excreta from 
patients receiving theranostic radiopharmaceuticals such as 
131I, 89Sr, 90Y, and 32P during course of their treatment and/or 
diagnosis, organic and aqueous solution obtained as a result 
of etching and dissolution of target materials during 
radioisotope production, contaminated blood samples of 
patient undergoing haematological studies, and 
radionuclides such as 14C and 3H employed for biochemical 
studies on metabolic pathway.  
Gaseous radiopharmaceutical waste 
Radiopharmaceutical waste in gaseous form arise during 
production and radiolabelling of various compounds, during 
treatment of solid and liquid waste, and as radioactive gases 
such as 133Xe, 81m Kr, and 18F used for investigation of 
pulmonary ventilation. 
RESULTS 
The existing scenario for radiopharmaceuticals guidelines in 
India concerning their storage and distribution has some 
limitations. In a move towards harmonization and fulfilling 
the regulatory void, a detailed regulatory guideline is 
presented which takes into account all form of radioactive 
wastes. Specifications regarding record keeping, 
responsibility, safety considerations, predisposal 
management, storage, packing, labelling, and disposal have 
been suitably addressed.   
Waste Prevention 
Segregation 
Recycle 
Treatment 
Disposal 
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1. General: Radiopharmaceutical waste arises from the 
production of radiopharmaceuticals and their use for various 
diagnostic and therapeutic purposes. The inherent 
hazardous nature of radiopharmaceutical waste necessitates 
immediate action for abatement, storage and further safe 
disposal so that threat to environment and public can be 
minimized. This mandates best practices to be followed right 
from the point of waste generation to the ultimate disposal. 
The emphasis of this guideline is on the protection of both 
people and environment from any undue exposure to 
ionizing radiation emanating from the radiopharmaceutical 
waste.  
2. Scope: This guideline is intended to cover all activities 
starting from generation to the acceptance of 
radiopharmaceutical waste, including spent and disused 
sealed sources, at its acceptance facility and the various 
procedures to be followed for the safe management, storage 
and disposal of radiopharmaceutical waste arising from their 
production and use. This guideline covers various techno-
managerial procedures and practices to be followed for safe 
handling, management, storage and disposal of 
radiopharmaceuticals waste. It emphasizes various 
approaches to ensure the establishment of correct 
procedures and its compliance so that the hazardous 
radioactive waste is appropriately stored and discarded 
following the best possible option.     
3. Protection of men and environment: The prime focus of 
all procedural set up and management practices in 
radiopharmaceutical waste management program should 
focus on protection of both men and environment from 
undue exposure from radiopharmaceutical wastes. Focus 
also needs to be made on the optimization of protection and 
safety standards so that the magnitude and extent of 
individual exposure, number of personnel exposed and the 
probability of exposure are all subjected to dose constraints 
having the regulatory approval for each practice concerned 
which should be commensurate to the applicable 
international standards.  
4. Roles and responsibilities: An effective 
radiopharmaceutical waste management program should 
encompass a clear allocation of roles and responsibilities 
that should be commensurate with the activity concerned 
and having the prime focus of achieving compliance to the 
various established national and international standards. 
The responsibility of radiopharmaceutical waste disposal 
rests with multiple levels of organization consisting of 
supplier (source supplier), the waste generator, waste 
manager and the authorized waste management agency 
consisting of radiological safety officer (RSO) and the 
regulatory body. 
The primary level of organization starts with producers of 
radiopharmaceutical cum ‘waste generators’ who are 
responsible for overall safe management of 
radiopharmaceutical waste and are involved in the 
collection, segregation, labelling,  characterization, 
classification, pretreatment, treatment, conditioning, 
packing, documentation, storage, and the disposal of 
radioactive waste. The waste generators should have the 
responsibility of safe management and execution of waste, 
including notification to the regulatory body in case of any 
event or accident. They should also ensure that adequate 
radiation protection of the workers, the general public and 
the environment are fulfilled at all the times and in 
compliance with the regulatory authority requirement.  It is 
also their responsibility to establish and implement the 
emergency preparedness associated with 
radiopharmaceutical waste management. Also, radiation 
safety officer and environmental management staff should 
bear the prime responsibility of arranging removal of wastes 
which have suitably decayed into non-radioactive waste 
during the course of their storage prior to disposal. In 
situations where predisposal management of waste is 
required and a need to transfer waste from one operator to 
other arise, a clear allocation of responsibility for each of the 
operation concerned to all the operators should be 
predefined.        
5. General safety consideration: Safety is of paramount 
importance while dealing with radiopharmaceutical waste. 
This part of guideline concerns the various safety 
considerations in radioactive waste management, facilities 
generating radioactive waste and the environmental impact 
assessment for an effective management of 
radiopharmaceutical waste. The safety consideration should 
include a choice of preferred option, control of waste 
generation and the characterization and classification of 
waste. Also important is to devise a safety culture, 
environmental monitoring mechanism and the emergency 
preparedness as a part of general safety consideration.  
6. Quality Assurance: A robust quality assurance program 
overseeing the entire process of radiopharmaceutical waste 
disposal provides confidence regarding optimal management 
and execution of each and every step according to the 
approved protocols. It helps to maintain all the records 
starting from waste collection to the final disposal of 
radiopharmaceutical waste which can be used as a reference 
for the safety of the site in the future. Quality assurance 
department should be made responsible for providing all the 
necessary training, control measures and audits for 
radiopharmaceutical waste disposal site and the associated 
aspects of radiation protection and operational procedures 
to be followed for best management of radiopharmaceutical 
waste.  
7. Waste Disposal - The Process 
Radiopharmaceutical waste disposal is an elaborated 
multiple step process consisting of management of waste 
from the point of its generation, storage to its final disposal. 
The various important stages in the life cycle of 
radiopharmaceutical waste management consist of the 
collection, pretreatment, treatment, conditioning, decay in 
storage and finally the disposal. Figure 2 below gives the 
pictorial view of various steps to be involved in 
radiopharmaceutical waste management process.   
 
 
Figure 2: Various steps to be involved in 
radiopharmaceutical waste disposal. 
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Briefly, the radiopharmaceutical waste, after collection, 
should be processed by various means to change its 
characteristics and convert it into a form amenable to 
disposal. This processing should essentially form the part of 
‘predisposal management’ after which it can be stored 
followed by decay and disposal. The storage should consist 
of placing the treated radiopharmaceutical waste until such 
time that it no longer comes under the purview of 
radioactive waste and can be disposed of as normal trash. In 
this method, the radiopharmaceutical waste, before disposal, 
should be stored in a secured place for a suitable amount of 
time to allow for the degradation of the radioactive nuclide 
of waste to its nonradioactive counterpart. Short half-life 
radioactive waste should be stored at the quarantined site of 
its generation for physical decay of activity. 
Radiopharmaceutical wastes of a high level of activity and 
long half-life radionuclides should be packed and suitably 
secured in the interim facility after segregation, treatment, 
conditioning and final disposal. The site for final disposal 
facility can be nationally or regionally situated depending 
upon the quantity and type for waste generated. Thus the 
waste management can be done both ‘onsite’ and ‘offsite’ at a 
specified waste management facility.  
7.1 Predisposal management of radiopharmaceutical 
waste: Following collection, the next step in 
radiopharmaceutical waste management should have 
appropriate predisposal management. It must consist of 
various processing steps that can change the characteristics 
of the waste. Various steps in predisposal management 
should include pretreatment, treatment and conditioning 
which can convert the waste into a form amenable to further 
processing. The various methods employed for processing 
should be selected based on the type of waste.  
7.1.1 Pretreatment: It should be the first step in 
radiopharmaceutical waste management and must consist of 
the collection, segregation and chemical adjustments. The 
collection and further segregation of waste should be done 
according to half-life, radionuclides, activity, and the physical 
form of waste. Segregation allows for volume reduction and 
cost saving of the entire waste management program. The 
waste should be placed in containers which are compatible 
both physically and chemically and provide its suitable 
containment. 
7.1.2 Treatment: The treatment of radiopharmaceutical 
waste should consist of various steps including chemical 
precipitation, ion exchange, ultrafiltration, immobilization 
and adsorption. For biological radioactive wastes, treatment 
option should focus on both radiological as well as non-
radiological hazard. Prior to treatment, the 
radiopharmaceutical waste, particularly the liquid waste, 
should be segregated in case they vary greatly in their 
chemical and radionuclide content. However, at all times, it 
should be ensured that the implications of secondary wastes, 
being generated as a result of treatment, should be given 
consideration in environmental impact and safety 
assessment. The secondary wastes should preferably be 
immobilized to produce a solid waste in a stable form which 
can be further managed.  
Recent advancement in waste management practices has 
resulted in the advent of new technology of advanced benefit 
and more safety. One such technology is ‘biochroma’ having 
chromatography based adsorption as final phase and can be 
suitably exploited for an effective management of liquid 
radiopharmaceutical wastes12.   
7.1.3 Conditioning: This should form the last stage in 
predisposal management of the radiopharmaceutical waste 
aiming to convert the processed waste into a form amenable 
to handling, storage and disposal. It should include matrix 
immobilization of waste or placing the waste into a container 
provided with additional packing for fragile wastes. This 
stage helps in removal of any free space in the container and 
ensure the prevention of leaching of container contents 
while in storage. Most of the radiopharmaceutical waste is 
short-lived and as such does not require any treatment.  
8. Packing prior to storage: Packing the radio- 
pharmaceutical waste constitutes one of the most critical 
operations in its safe disposal. The primary aim of packing 
should be to secure waste in a proper form and prevent the 
release of potential contaminants. This can be achieved by 
double containment in which the waste such as liquid is 
placed in a closed bottle inside a spill container or a plastic 
bag inside hard plastic bucket for solid wastes or even 
double plastic bags sealed individually. It is prudent to pack 
the waste in as small as possible container relevant to waste 
accumulated as it prevents wastes being collected over a 
long period of time. The bag should be of sufficient strength 
to withhold the waste and should have the option to seal 
with cable tie as it facilitates easy opening of the bag when 
required. Primary packs should preferably be transparent as 
it helps in easy identification of waste without the need of 
opening it. For solid wastes, leak-proof plastic bags or sharps 
containers are advisable. Scintillation vials, appropriately 
secured in approved containers, should be used to dispose of 
the liquid wastes.  
9. Labelling requirements for wastes: Proper labelling of 
the radiopharmaceutical waste is another important 
regulatory requirement and should be commensurate to its 
stage. Separate labelling requirements exist for waste 
corresponding to different stage. Label for waste collection, 
also called ‘in use’ label, should consist of only basic 
information concerning the radiopharmaceutical wastes like 
the type of radionuclide present and the details of waste 
generator. These labels are required while the waste is being 
collected. The collection of radiopharmaceutical waste 
should generally be done in primary containers which can be 
securely sealed in a secondary container. There is no specific 
label requirement for primary containers as long as they are 
kept within secondary containers. This facilitates an easy 
disposal of waste present in a primary container at the time 
of disposal as it is ideally free of any label bearing sign of 
radioactivity at the time of disposal. However, the secondary 
container label should have all the details of waste consisting 
of type of radionuclide present, its physical form, and its 
radioactivity at the time of packing. A three level of packing 
is recommended here to better ensure the correctness of the 
label according to its stage.  
 Primary packing: Clear bag sealed appropriately with a 
cable tie.  
 Secondary packing: Having proper waste disposal label. 
 Tertiary packing: Brightly coloured bag appropriately 
sealed with a cable tie which can be removed before 
disposing of the waste.    
10. Storage of radiopharmaceutical waste: After suitable 
pretreatment of radiopharmaceutical waste, they should be 
further subjected to storage in suitable waste storage 
facilities until the time they have suitably decayed to its 
nonradioactive part. The radiopharmaceutical waste should 
be stored in a manner so as to allow suitable inspection, 
monitoring, and preservation during the storage time. The 
management approach to storage should be to place the 
radiopharmaceutical waste in a suitable waste storage 
facility, with adequate shielding consisting of lead or 
concrete block according to the complexity of the operation, 
as a part of their ‘decay in storage’ program. This approach 
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to radiopharmaceutical waste management is equally 
suitable to all physical states of waste and can be easily 
applied to waste having half-lives of less than 100 days as 
per International Atomic Energy Agency recommendations. 
The primary objective of storage should be isolation and 
containment of waste for a period of time during which it 
decays to its non-radioactive part and can be treated as 
normal waste. During storage, it is important to have full 
traceability of waste packages by suitable record keeping. 
Also important is to do periodic monitoring of such site for 
establishing safety during the course of their storage. A dose 
limit of 1mSv per year at the boundary of the radiological 
facility as suggested by the International Commission on 
Radiological Protection should be referred for confirming 
safety aspect during storage of radioactive wastes.  
Majority of radiopharmaceutical waste consists of 
radionuclides having a half-life ranging from a few hours to 
months and can be effectively managed using this approach 
alone. Table 1 below presents a list of most commonly used 
medical radioisotopes for various purposes that can be 
managed using ‘decay in storage’ approach. 
  
Table 1: Presenting the most commonly used medical radioisotopes which can be disposed of following ‘delay and decay’ 
approach. 
Sr. No. Isotope Half-life Application Type of Waste 
1 18F 1.83 h PET imaging Solid, liquid 
2 24Na 15.0 h Clinical measurement Liquid 
3 32P 14.3 d Therapy Solid, liquid 
4 59Fe 44.5 d Clinical measurements Liquid 
5 58Co 70.8 d Clinical measurements Solid, liquid 
6 67Ga 3.26 h Clinical measurement Liquid 
7 89Sr 50.5 d Therapy Liquid 
8 99mTc 6.02 h Clinical measurement Solid, liquid 
9 125I 60.1 d Clinical measurement, labelling Solid, liquid 
10 131I 8.04 d Clinical measurement, therapy Solid, liquid 
 
After securely placing radioactive wastes in suitably shielded 
lead-lined containers, they should then be allowed to go for 
‘decay in storage’ in which a minimum storage of 10 half-
lives should be achieved. This period is generally 
recommended as it is adequate to reduce the initial activity 
of waste to less than one-thousandth of the initial activity. 
The waste should be sufficiently held in storage until the 
radiation exposure rate cannot be distinguished from the 
background radiation levels. On successful completion of 
decay period, the dose rate emanating from these wastes 
should be recorded before moving to the next step of final 
disposal.  On all occasions, it should be ensured that the 
clearance level has been achieved. The radioactive waste 
must be monitored at the surface of the container with an 
appropriate radiation detection instrument set at its most 
sensitive scale and with no interposed shielding between the 
detector and the waste, in a low background radiation 
environment. Once the radioactive waste has decayed 
sufficiently and a confirmation is made for the absence of 
radioactivity, they should be disposed of as chemical, 
biological or industrial waste as regular trash. Segregation of 
waste should also be done at the end of the decay storage 
period based on remaining activity. 
The radiopharmaceutical waste should be stored/disposed 
of depending upon its state as elaborated below: 
10.1 Solid wastes: For storage of solid wastes, the following 
procedure should be adopted.  
 Various syringes, scintillation vials, scalpels blades and 
hypodermic needles constituting the sharp items 
generated as radioactive wastes should be securely 
deposited in lead-lined sharp bins and labelled with 
caution about radioactivity. Outside of all these 
containers should be swiped and tested for radioactivity 
using a well counter. The radioactive sharp material 
container should be placed in a hot secured area for 
sufficient decay after putting it into a secondary 
container which further helps in preventing breakage of 
these susceptible items. An option for placing an 
absorbent pad in the secondary container should also be 
used for preventing any leakage.   
 Radioactive wastes consisting of absorbent paper and 
gloves should be separately placed in another container 
which is also appropriately shielded and labelled.     
 Solid wastes consisting of carcasses of experimental 
animals and blood-contaminated wastes should be 
hermetically sealed using polyethylene drums instead of 
plastic bags. It is generally recommended to first 
deactivate the waste using autoclaving or chemical 
disinfection and then storing it in the freezer. 
Putrescible waste consisting of carcasses of 
experimental animals should be stored in a deep freezer 
for preventing any biological decay during its transition 
to non-radioactive waste. Frost free deep freezer is 
generally recommended for preventing off-gas 
phenomenon which could otherwise cause trapping of 
radioactive material into the frost buildup.  
 Lead pots should be suitably decontaminated prior to 
reuse or recycling as nonradioactive wastes.  
 For radionuclide generator, the best practice is to go for 
‘decay in storage’ option followed by dismounting the 
elution column from its shield. However, it should be 
ensured that the activity and dose rate should be low 
before removal of the elution column followed by its 
dismantling. No special requirements exist for disposal 
of radionuclide generator except for appropriate 
surveys to confirm total decay and removal of labels 
from the devices. When the generator activity has 
decayed to background levels, the radionuclide 
generator can be disposed of in non-radioactive trash.  
 
Sealed radioactive sources have different half-lives and 
activity and are used for varied purposes in nuclear medicine 
and radiotherapy departments. Depending on the activity 
and half-lives of radionuclide content, these sealed sources 
at end of their useful life should be disposed of suitably as 
disused sealed sources. They may emit intense radiations 
and exceeds the recommended specific activity to be 
accepted as normal trash. Therefore different approaches 
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should be used for disused sealed sources. It may consist of 
disposal following decay in storage, near-surface disposal 
facilities or even deep geological disposal depending upon 
the level of isolation required. Also returning to the supplier 
can be a practical option in some cases. For sealed sources 
having a short half-life (about 100 days) and of reasonably 
high activity, the ‘decay in storage’ is the preferred option. 
However, for sources having a very high level of activity and 
a long physical half-life, the ‘decay in storage’ method is not 
recommended as they can constitute high localized 
concentration inside the facility requiring long-term storage 
problems and the associated risk in cases of human intrusion 
leading to widespread complications. Therefore, at the end of 
their useful half live, these high activity long half- live 
sources should be disposed of as disused sealed radioactive 
source in borehole facilities. It should consists of placing the 
waste containing radionuclide in a specially engineered 
facility having a narrow diameter bored which can be 
operated directly from the surface. The most important 
aspect for management of disused sealed sources should be 
the maintenance of continuity of control irrespective they 
are in use or not. This is because they may contain 
radionuclide in a dispersible form which can create 
widespread havoc should their primary containment is 
breached. Figure 3 presents an overview of different 
approaches to be followed for waste management of disused 
sealed sources. 
    
 
Figure 3: Different approaches to be followed for the management of disused sealed sources. 
 
10.2 Liquid wastes: Radiopharmaceutical waste obtained as 
liquid should be disposed of as follows: 
 As in all cases, the initial step towards disposal of liquid 
waste should be segregation of short half-life 
radiopharmaceutical waste from long half-life. Short 
half-life radiopharmaceuticals include those containing 
Tc99m and F18 while long half-life includes 
radiopharmaceuticals containing Lutetium 177.  
 For radiopharmaceuticals containing intermediate half-
life radionuclides like I131, I123, and Ga67, following the 
decay in storage approach is advisable.  
 Patients undergoing diagnostic scans are administered 
radiopharmaceuticals of short half-life in a very limited 
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Supplier 
Disused Sealed Sources 
Is the Source Leaking? 
Conditioning  
Possible to Reuse 
Segregation and 
Characterization 
 
Short Half Life  
 
Long Half Life  
 
Decay in Storage Interim Storage 
Managed as Non-
Radioactive Waste   
Deep Geological 
Disposal / Borehole 
Facility  
No 
Yes 
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amount. Therefore excreta from such patients can be 
discharged into the sewerage system directly provided 
they are centrally connected to the sewerage 
management system.   
 Radioactive organic and aqueous wastes should be 
stored and disposed of separately even if they have the 
same radionuclide in them.  
 Contaminated solution arising from rinsing activity of 
various apparatus of radioimmunoassay kits is diluted 
to a large extent and can be discharged directly through 
the hospital sewerage system to municipal waste. For 
disposal through sewerage, the most important point to 
confirm is the solubility of material to be disposed of in 
water.  
 For managing excreta of inpatients on 
radiopharmaceutical therapy and diagnosis in hospital 
nuclear medicine department, best option should be to 
design the outlet of toilets being used by these 
inpatients and route it to delay tanks via leak proof 
pipes. These delay tanks may be of the size of the 
swimming pool with adequate shielding. Biochroma 
technique can be suitably employed in this case.     
 Radioactive liquid waste can also be allowed to suitably 
undergo decay into a nonradioactive form using delay 
tanks made of concrete with suitable shielding. The 
activity at the end of the decay period from these tanks 
should be recorded by adequate sampling and after 
confirmation of permissible limits should be discharged 
to the community sewerage system.  
 
10.3 Gaseous Waste: Radioactive gaseous waste should be 
treated at the point of its origin itself. The setup should 
consist of a condenser, pre-filter followed by HEPA filters. 
The function of condenser should be to condense the 
radioactive gaseous waste which is then filtered through the 
prefilter. The final exhaust of gas consists of passing the 
prefiltered gas through HEPA filter fitted at the exhaust end 
of chimney installed at an appropriate height.  
11. Near-surface disposal of solid waste: For solid 
radiopharmaceutical waste which has sufficiently undergone 
disintegrations into its non-radioactive form, the subsequent 
steps should consist of suitably disposing these 
nonradioactive wastes to landfills or ‘near surface disposal of 
solid waste’. Near-surface disposal consists of emplacement 
of solid radioactive waste having short-lived radionuclides in 
a disposal facility that is located few meters underground in 
form of earthen trenches or engineered structures. 
The basic concept of ‘containment and isolation’ is followed 
for near-surface disposal method. Containment should be 
achieved by using engineered barriers like the waste 
package, facility structure and even the geological layers 
within the facility. The site to be selected for such disposal 
purpose should be sufficient to accommodate the waste and 
be suitably located keeping in mind all the socio-economic 
and environment management factors. The design and 
layout of the site should be pre-approved from the 
regulatory authority. Provision for monitoring and 
surveillance during operation and post-closure phases 
should also be made available in waste disposal facility for 
verification of its containment capability.  
The most important thing to be kept in mind for the site at 
which the final disposal of radiopharmaceuticals waste is to 
be done is that safety requirements should be commensurate 
with the longevity of the hazard (i.e. the amount and 
concentration of radionuclides) along with environmental 
conditions at the disposal site. Also important to keep in 
mind is the geology, seismic vulnerability, and the 
topographical location of the facility. Areas amenable to 
earthquake, flood and erosion should be avoided. The site 
should have a multi-barrier approach to assist 
radiopharmaceutical waste isolation from the biosphere for 
a suitable amount of time depending on the type of waste. 
The final closure of near-surface disposal facility should be 
done after approval from the regulatory authority on 
successful submission of closure and safety assessment plan. 
Suitable markers for identification of these disposal sites 
should be done for its easy identification for future. 
Precautions should be taken for preventing any human 
intrusion, land use or the removal of waste from the site. 
12. Documentation: It is indispensable for all 
radiopharmaceutical waste management program to have 
written records of each and every step in the overall waste 
management life cycle. Also, records should be available for 
the design, layout, closure and post-closure of waste 
management facility. Documentation should consist of 
necessary details regarding the inventory of stock, including 
its location, and its physical and chemical characteristics. 
Records should be maintained/retained in multiple copies 
for waste disposal facility till the activity level, as measured 
using suitable counters, reaches a safety level. It is important 
to maintain the records of the disposal of licensed materials 
for 3 years. The record must include the date of disposal, the 
survey instrument used, the background radiation level, the 
radiation level measured at the surface of each waste 
container, and the name of the individual who performed the 
disposal. Most critical aspect deals with the waste storage 
step in which many radiopharmaceutical wastes are 
collected and stored at the same time in a waste store. 
Therefore full details of each and every waste package 
should be maintained in a radioactive waste register before 
its acceptance into the waste store. It should consist of 
details like radionuclide present, date of its generation, date 
of acceptance, its current activity, its physical state, and 
precautions if any. The waste should also be provided with a 
unique identification number in a suitable format like XX-YY-
ZZ where XX denotes serial number of the packet, YY denotes 
the date on which the packet was received and ZZ denotes 
the year. A typical format for radiopharmaceutical waste 
register is presented in table 2 below: 
 
Table 2: Contents and format of the radioactive waste register. 
 Date 
Waste 
Generated 
Waste 
Register 
Number 
(XX-YY-ZZ) 
Radio-
nuclide 
Present 
Waste 
Generator 
Current Activity/ 
Measurement 
Date 
Type (Solid/ 
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Records should also be maintained for all material from 
which the regulatory control has been withdrawn following 
suitable decay including details of all spent and/or disused 
sources being returned to their suppliers. 
DISCUSSION 
Existing national laws and policies should be revised to 
devise a coherent, comprehensive and consistent set of 
standards that are of international level for holistically 
dealing with existing regulatory concerns regarding 
radiopharmaceutical storage and disposal. The focus needs 
to be drawn for assessing the available option for waste 
management and the search for better alternatives. A 
detailed study of various nuclear medicine procedures being 
performed annually in India along with the associated waste 
generated needs to be done for assessing and investigating 
the present capacity of various hospitals in dealing with 
radiopharmaceutical waste. This will provide the lead for 
construction of waste repositories at the regional and/or 
national level. 
The facility for disposal of spent sealed sources of long half-
lives using deep geological method should be flexible enough 
to address the ongoing technological advances at the outset. 
Periodic audits, including unplanned inspection, should be 
done by national authorities in an independent manner to 
ensure full compliance to the approved procedures which 
will help in building public trust and transparency. Most 
importantly, a study on each of the radiopharmaceutical 
being used in healthcare and nuclear medicine should be 
done to reach at an agreed set of activities and activity 
concentration to be used for different age group and the 
acceptance level for disposal to landfill, sewer or 
atmosphere. This will help in promoting a uniform approach 
to radiopharmaceutical waste disposal.      
CONCLUSION 
As new radiopharmaceuticals are making their way to the 
market, the issue concerning their storage and disposal 
needs considerable attention. There is an indispensable need 
of adequate regulatory guidelines so that 
radiopharmaceuticals are stored and disposed of in the most 
judicious manner, taking into consideration both men and 
the environment. Any new radiopharmaceutical being 
launched into the market should have a full life cycle 
regulatory plan consisting of ways to minimize waste during 
its production and use along with its final disposal as a part 
of its cradle-to-grave approach.  
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